Frederick J Lang

US Patent:

20030138405, Jul 24, 2003

Filed:

Apr 17, 2002

Appl. No.:

10/124608

Inventors:

Juan Fueyo - Houston TX, US
Athanassios Kyritsis - Stavraki, GR
Polly Lee - Houston TX, US
Victor Levin - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houston TX, US

International Classification:

A61K048/00
C12N007/00
C12N015/861

US Classification:

424/093200, 435/235100, 435/456000

Abstract:

The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.

US Patent:

20060147420, Jul 6, 2006

Filed:

Mar 10, 2005

Appl. No.:

11/077513

Inventors:

Juan Fueyo - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houston TX, US

International Classification:

A61K 48/00

US Classification:

424093200

Abstract:

The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

US Patent:

20070292396, Dec 20, 2007

Filed:

Mar 2, 2007

Appl. No.:

11/681592

Inventors:

Juan Fueyo - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houston TX, US

International Classification:

A01N 63/00
A61K 38/00
A61P 43/00

US Classification:

424093600, 514002000

Abstract:

The present invention involves compositions and methods for treating cancer using a combination of cell cycle modulating agent(s) and anticancer agents or therapies, particularly S-phase specific therapies.

US Patent:

20140377221, Dec 25, 2014

Filed:

Jan 25, 2013

Appl. No.:

14/374619

Inventors:

- Houston TX, US
- Austin TX, US
Frederick Lang - Houston TX, US
Amy Heimberger - Houston TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
DNATRIX INC. - Houston TX

International Classification:

A61K 35/76
A61K 38/21
C07K 16/28
A61K 39/395
C12N 7/00
G01N 33/574
A61K 38/20

US Classification:

424 852, 506 9, 424 936, 424 855, 4241421

Abstract:

The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.